BBIO Quote, Financials, Valuation and Earnings

Pfizer has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 25.23%. BridgeBio Pharma's return on equity of -- beat Pfizer's return on equity of 4.63%.

BridgeBio Pharma has a consensus price target of $48.56, signalling upside risk potential of 76.07%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.29%. Given that BridgeBio Pharma has higher upside potential than Pfizer, analysts believe BridgeBio Pharma is more attractive than Pfizer.

BridgeBio Pharma has a beta of 1.079, which suggesting that the stock is 7.928% more volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.29% to investors and pays a quarterly dividend of $0.42 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Pfizer quarterly revenues of $17.7B. BridgeBio Pharma's net income of -$162M is lower than Pfizer's net income of $4.5B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 23.25x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 36.03%. BridgeBio Pharma's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

BridgeBio Pharma has a consensus price target of $48.56, signalling upside risk potential of 76.07%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.26%. Given that BridgeBio Pharma has higher upside potential than Regeneron Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Regeneron Pharmaceuticals.

BridgeBio Pharma has a beta of 1.079, which suggesting that the stock is 7.928% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. BridgeBio Pharma's net income of -$162M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 23.25x versus 5.94x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of --. BridgeBio Pharma's return on equity of -- beat Cassava Sciences's return on equity of --.

BridgeBio Pharma has a consensus price target of $48.56, signalling upside risk potential of 76.07%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4713.28%. Given that Cassava Sciences has higher upside potential than BridgeBio Pharma, analysts believe Cassava Sciences is more attractive than BridgeBio Pharma.

BridgeBio Pharma has a beta of 1.079, which suggesting that the stock is 7.928% more volatile than S&P 500. In comparison Cassava Sciences has a beta of -0.856, suggesting its less volatile than the S&P 500 by 185.551%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $2.7M, which are larger than Cassava Sciences quarterly revenues of --. BridgeBio Pharma's net income of -$162M is lower than Cassava Sciences's net income of -$27.9M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 23.25x versus 2.64x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 37.71%. BridgeBio Pharma's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

BridgeBio Pharma has a consensus price target of $48.56, signalling upside risk potential of 76.07%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 21.8%. Given that BridgeBio Pharma has higher upside potential than Vertex Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Vertex Pharmaceuticals.

BridgeBio Pharma has a beta of 1.079, which suggesting that the stock is 7.928% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. BridgeBio Pharma's net income of -$162M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 23.25x versus 9.93x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.